Search

Your search keyword '"Tamamura H"' showing total 49 results

Search Constraints

Start Over You searched for: Author "Tamamura H" Remove constraint Author: "Tamamura H" Topic peptides Remove constraint Topic: peptides
49 results on '"Tamamura H"'

Search Results

1. Discovery of a Macropinocytosis-Inducing Peptide Potentiated by Medium-Mediated Intramolecular Disulfide Formation.

2. Delivery of a Proapoptotic Peptide to EGFR-Positive Cancer Cells by a Cyclic Peptide Mimicking the Dimerization Arm Structure of EGFR.

Catalog

Books, media, physical & digital resources

3. Bivalent 14-mer peptide ligands of CXCR4 with polyproline linkers with anti-chemotactic activity against Jurkat cells.

4. Development of anti-HIV peptides based on a viral capsid protein.

5. Multimerized HIV-gp41-derived peptides as fusion inhibitors and vaccines.

6. Functional evaluation of fluorescein-labeled derivatives of a peptide inhibitor of the EGF receptor dimerization.

7. Exploration of labeling by near infrared dyes of the polyproline linker for bivalent-type CXCR4 ligands.

8. Trivalent ligands for CXCR4 bearing polyproline linkers show specific recognition for cells with increased CXCR4 expression.

9. CXCR4-derived synthetic peptides inducing anti-HIV-1 antibodies.

10. Cell-permeable stapled peptides based on HIV-1 integrase inhibitors derived from HIV-1 gene products.

11. Anti-HIV-1 peptide derivatives based on the HIV-1 Co-receptor CXCR4.

13. Peptidic HIV integrase inhibitors derived from HIV gene products: structure-activity relationship studies.

14. Peptide HIV-1 integrase inhibitors from HIV-1 gene products.

15. [Peptidomimetic-based medicinal chemistry].

16. Development of crosslink-type tag-probe pairs for fluorescent imaging of proteins.

17. Inhibitory effect of newly developed CXC-chemokine receptor 4 antagonists on the infection with feline immunodeficiency virus.

18. Fluorogenically active leucine zipper peptides as tag-probe pairs for protein imaging in living cells.

20. Development of peptide-targeted lipoplexes to CXCR4-expressing rat glioma cells and rat proliferating endothelial cells.

21. Therapeutic potential of the chemokine receptor CXCR4 antagonists as multifunctional agents.

23. Facile synthesis of membrane-embedded peptides utilizing lipid bilayer-assisted chemical ligation.

24. A single treatment with microcapsules containing a CXCR4 antagonist suppresses pulmonary metastasis of murine melanoma.

25. CXCR4 antagonist inhibits stromal cell-derived factor 1-induced migration and invasion of human pancreatic cancer.

26. T140 analogs as CXCR4 antagonists identified as anti-metastatic agents in the treatment of breast cancer.

27. Stereoselective synthesis of CF(2)-substituted phosphothreonine mimetics and their incorporation into peptides using newly developed deprotection procedures.

28. An automated prediction of MHC class I-binding peptides based on positional scanning with peptide libraries.

29. Efficient induction of peptide-specific cytotoxic T lymphocytes by LPS-activated spleen cells.

30. Inhibitory mechanism of the CXCR4 antagonist T22 against human immunodeficiency virus type 1 infection.

31. Marked increase in anti-HIV activity, as well as inhibitory activity against HIV entry mediated by CXCR4, linked to enhancement of the binding ability of tachyplesin analogs to CXCR4.

32. Pharmacophore identification of a chemokine receptor (CXCR4) antagonist, T22 ([Tyr(5,12),Lys7]-polyphemusin II), which specifically blocks T cell-line-tropic HIV-1 infection.

33. Downsizing of an HIV-cell fusion inhibitor, T22 ([Tyr5,12, Lys7]-polyphemusin II), with the maintenance of anti-HIV activity and solution structure.

34. Effective lowly cytotoxic analogs of an HIV-cell fusion inhibitor, T22 ([Tyr5,12, Lys7]-polyphemusin II).

35. A small molecule CXCR4 inhibitor that blocks T cell line-tropic HIV-1 infection.

36. An anti-HIV peptide, T22, forms a highly active complex with Zn(II).

37. Analysis of the interaction of an anti-HIV peptide, T22 ([Tyr5, 12, Lys7]-polyphemusin II), with gp120 and CD4 by surface plasmon resonance.

38. Interaction of an anti-HIV peptide, T22, with gp120 and CD4.

39. The synthetic [Tyr5,12,Lys7]-polyphemusin II peptide (T22) binds to the CD4 cell surface molecule.

40. Synthesis of protegrin-related peptides and their antibacterial and anti-human immunodeficiency virus activity.

41. Disulfide bond-forming reaction using a dimethyl sulfoxide/aqueous HCl system and its application to regioselective two disulfide bond formation.

42. Solution-phase synthesis of an anti-human immunodeficiency virus peptide, T22 ([Tyr5,12,Lys7]-polyphemusin II), and the modification of Trp by the p-methoxybenzyl group of Cys during trimethylsilyl trifluoromethanesulfonate deprotection.

43. Structure-activity relationships of an anti-HIV peptide, T22.

44. Fine structure of a virus-encoded helper T-cell epitope expressed on FBL-3 tumor cells.

45. Molecular parameters for the anti-human immunodeficiency virus activity of T22 ([Tyr5,12, Lys7]-polyphemusin II).

46. Lymphocytes and promonocytes attach to the synthetic [Tyr5,12, Lys7]- polyphemusin II peptide.

47. A comparative study of the solution structures of tachyplesin I and a novel anti-HIV synthetic peptide, T22 ([Tyr5,12, Lys7]-polyphemusin II), determined by nuclear magnetic resonance.

48. Acceleration of the N alpha-deprotection rate by the addition of m-cresol to diluted methanesulfonic acid and its application to the Z(OMe)-based solid-phase syntheses of human pancreastatin-29 and magainin 1.

49. A novel anti-HIV synthetic peptide, T-22 ([Tyr5,12,Lys7]-polyphemusin II).